Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02045693 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction & Methadone & Buprenorphine
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02045693: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT02045693 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02045693, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in subjects with the stable dose of Methadone and on the PK of Buprenorphine in subjects with the stable dose of Buprenorphine.
Interventions
- DRUG Methadone
- DRUG Buprenorphine
- DRUG Naloxone
- DRUG BMS-791325
- DRUG DCV 3DAA FDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
What the finished NCT02045693 record still lists
NCT02045693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 5 interventions - of which Methadone is the first listed.
NCT02045693 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02045693 about?
NCT02045693 is a clinical study titled "Drug Interaction & Methadone & Buprenorphine". The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in subjects with the stable dose of Methadone and on the PK of Buprenorphine in subjects with the stable dose of Buprenorphin...
What is the current status of trial NCT02045693?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02045693?
The interventions under investigation include: Methadone (DRUG), Buprenorphine (DRUG), Naloxone (DRUG), BMS-791325 (DRUG), DCV 3DAA FDC (DRUG).
Who is sponsoring clinical trial NCT02045693?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02045693's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia